• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
HEPA

HEPA

Hepion Pharmaceuticals, Inc.

OTCHealthcareBiotechnologyUS

USD0.06

-0.00 (-4.76%)

Rating:B-

Company Profile

CEO

Gary S. Stetz

IPO Date

2014-02-10

Sector

Healthcare

Industry

Biotechnology

Exchange

OTC

Country

US

Market Metrics

Open

$0.06

Prev. Close

$0.06

Day Low

$0.06

Day High

$0.06

52W Low

$0.03

52W High

$0.25

Market Cap

$0.00B

Volume

0.02M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

46.3%

Avg Negative

10.0%

Avg Neutral

43.6%

News Feed

Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders

GlobeNewsWire·7/23/2021·↓ negative

Hepion Pharma's NASH Candidate Aces Mid-Stage Study

Benzinga·7/13/2021·↑ positive

Hepion Pharmaceuticals Announces Adjournment of Annual Meeting

GlobeNewsWire·6/25/2021·↓ negative

Hepion Pharmaceuticals to be Added to the Russell Microcap® Index

GlobeNewsWire·6/9/2021·↑ positive

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH

GlobeNewsWire·5/6/2021·↑ positive

Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress

GlobeNewsWire·4/29/2021·↑ positive

HEPA Stock Price Increases Over 5% Pre-Market: Why It Happened

Pulse2·3/23/2021·↑ positive

DIAMOND Mouse Model is Latest in a String of Nonclinical Studies Confirming the Antifibrotic Effects of Hepion Pharmaceutical's Lead Drug, CRV431

GlobeNewsWire·3/23/2021·↑ positive

Hepion Pharmaceuticals Announces Pricing of Public Offering

GlobeNewsWire·2/16/2021·↑ positive

Attractive Risk-Reward Profile For Hepion Pharmaceuticals

Seeking Alpha·2/12/2021·↑ positive